Junshi Bio announced that its wholly-owned subsidiary product Teripulimab monoclonal antibody (United Kingdom commodity name: LOQTORZI) has obtained the listing approval issued by the United Kingdom Pharmaceutical and Healthcare Products Regulatory Agency (MHRA), approved for the treatment of two indications: 1. Teripulimab monoclonal antibody combined with cisplatin and gemcitabine for first-line treatment in adults with recurrent, unresectable or refractory, or metastatic nasopharyngeal carcinoma; 2. Teripulimab monoclonal antibody combined with cisplatin and paclitaxel for first-line treatment in adults with unresectable advanced/recurrent or metastatic esophageal squamous cell carcinoma. Teripulimab monoclonal antibody becomes the first and only drug used for the treatment of nasopharyngeal carcinoma in the United Kingdom and also the only first-line treatment drug for advanced or metastatic esophageal squamous cell carcinoma with no limitation on PD-L1 expression in the United Kingdom.